EANS-News: AGENNIX AG / Agennix AG Announces Data from Talactoferrin Phase II Trial in Severe Sepsis to be Presented at 40th Critical Care Congress of the Society of Critical Care Medicine

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development/Severe Sepsis

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, January 12, 2011 - Agennix AG (Frankfurt Stock Exchange:
AGX) today announced that new and more detailed data from a Phase II
trial in severe sepsis with talactoferrin, an oral biologic therapy
with immunomodulatory and antibacterial properties, will be presented
at the 40th Critical Care Congress of the Society of Critical Care
Medicine, to be held January 15-19, 2011 in San Diego, California.

Talactoferrin-related presentations are as follows:

"Talactoferrin alfa reduces 3 and 6 month all-cause mortality in
patients with severe sepsis," will be part of the oral session,
"Infectious Disease-Sepsis," to be held on January 16, 2011,
3:00-5:00 PM.

"Talactoferrin may confer increased survival in patients with septic
shock and systolic cardiac dysfunction," will be presented as a
poster presentation in the Therapeutics-Drugs and Pharmacokinetics-2
category.

About talactoferrin Talactoferrin is an oral biologic therapy with
immunomodulatory and antibacterial properties, which is being studied
for the treatment of cancer and severe sepsis. Talactoferrin has
demonstrated activity in randomized, double-blind, placebo-controlled
Phase II studies in non-small cell lung cancer (NSCLC), as well as in
severe sepsis. As a result of the promising results from Phase II
studies, two Phase III trials with talactoferrin in NSCLC have been
initiated. NSCLC is one of the most common types of cancer worldwide
and the most frequent cause of cancer death. Agennix also plans to
develop talactoferrin further for the treatment of severe sepsis and
expects to initiate the Phase II portion of a Phase II/III trial in
that indication in March/April 2011. Talactoferrin has been shown to
be very well tolerated in these patient populations.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company´s most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III
clinical trials in non-small cell lung cancer, and Agennix plans to
develop this program further for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase 1 testing; and a topical gel
form of talactoferrin for diabetic foot ulcers. Agennix´s registered
seat is in Heidelberg, Germany. The Company has three sites of
operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. There can be no
guarantee that the Company will move talactoferrin forward in
development for severe sepsis in a timely manner, if at all, or that
talactoferrin will ultimately be approved for sale in any indication
in any country. Actual results could differ materially depending on a
number of factors, and we caution investors not to place undue
reliance on the forward-looking statements contained in this press
release. Forward-looking statements speak only as of the date on
which they are made and Agennix undertakes no obligation to update
these forward-looking statements, even if new information becomes
available in the future.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Agennix AG
Barbara Mueller
Manager, Investor Relations &
Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations &
Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0)89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade